Tao of stenting – J&J’s yin
This article was originally published in The Gray Sheet
Executive Summary
First full quarter of drug-eluting stent sales in U.S. generates $429 mil. in revenue, accounting for 45% of all U.S. stent procedures and 90% of Johnson & Johnson's overall Q3 stent sales. Internationally, Cypher produced roughly $60 mil. in revenue. General medical devices and diagnostic sales increased 20%, to $3.78 bil., outshining pharmaceuticals, which only saw a 13% gain, to $4.84 bil...